This has been termed a "retrospective diagnosis" of acute myocardial infarction [2] .
Unfortunately,
given the ubiquity of LD in a large number of tissues, determinationsof LD isoenzymes present problems of specificity [10] . Criteriafor LD measurements that maximize sensitivity often do so at the expense of specificity [4] ,and criteria proposed to improve specificity reduce sensitivity. Thus, development of tests that are more specific than those for LD isoenzymes would substantially facilitate the retrospective diagnosis of infarction.
Cardiac troponin I (cTnl), a sensitive [11] and highly specific [12] [13] [14] marker for cardiac injury, recently has been approved by the US Food and Drug Administration for clinical use. In comparative studies with MBCK, cTnI has been shown to be more specific [12] [13] [14] but comparably sensitive for damaged heartmuscle [11] . Preliminary data indicatethatits detection in serum afteracute infarction occurs in a time course similar to thatof MBCK but with more-prolonged high values [15] . These prolonged increases have been attributed to the slow release of cTnI, which is bound to the contractile apparatus of heart muscle [11, 16] . However, the durationof the increases of cTnI and its sensitivity forthe diagnosisof acuteinfarction over time have not been rigorously assessed. Accordingly, we undertook the following study to determine the sensitivity of cTnI in 
BLOOD SAMPLING
Daily serum or heparinized plasma samples were collected from the day of admission until discharge from the hospital. Samples were processed in the clinical chemistry laboratory of Barnes Hospital.
LD isoenzymes
were measured within 24 h from serum samples stored at room temperature; heparinized plasma samples were not assayed for LD isoenzymes.
Aliquots of the samples were frozen at -70 #{176}C for subsequent measurement of cTnI.
BIOCHEMICAL MEASUREMENTS
The ratio of LD1ILD2 isoenzymes was determined in the clinical chemistry laboratory at Barnes Hospital by using agarose electrophoresis (Paragon system; Beckman, Fullerton, CA) to separate the LD isoenzymes eletrophoretically and then quantifying their activity by their NADPH fluorescence. Electrophoretic methods have been reported to have variable accuracy [17] . To evaluate the diagnostic value of the LD isoenzymes, we used two different upper reference limits: LD1/LD2 1, which is thought to enhance specificity, and LD1ILD2 0.8, which is thought to enhance sensitivity [2, 3] .
cTnI values were determined in serum or heparinized samples by an immunoassay in a preliminary commercial application on the Stratus II immunoanalyzer (Dade International, Miami, FL). The limit of detection with this assay is 0.4 p.gfL. We also compared the results of this assay with those of the research application immunoassay previously used in our laboratory [12] . Biochemical values were assessed by one of us (JHL), who was unaware of all other clinical information, and patients with increases of cTnI suggestive of extension of infarction were excluded from analysis.
ECG ANALYSIS
All EGGs obtained for patients during hospitalization were collected and reviewed by one of us (EMG), who was unaware of any of the patients' clinical or biochemical information. Patients were classified into groups with Q-wave infarction if new Q-waves developed in two contiguous leads or groups with non-Q-wave infarction if Q-waves did not evolve. Those in whom EGG evidence suggested extension of infarction were excluded.
CLINICAL FOLLOW-UP
All patients were monitored daily by a research nurse who was supervised by one of us (ASJ). Patients deemed clinically to have extension of infarction were eliminated from the study without reference to the cTnI data.
IN VIVO CLEARANCE OF CTNI
Studies of the in vivo clearance of cTnI used affinity-purified cTnI extracted from dog heart as previously described [18] . The cTnI was dialyzed against 50 mmol/L Tris, pH 7.3, containing 150 mmol/L NaCI.
Five to 10 mg of cTnI was injected intravenously as a bolus into each of three conscious dogs who were lightly sedated with morphine (0.5 big/kg given subcutaneously). Venous blood samples were obtained before injection and serially up to 300 mm after injection.
Concentrations of cTnI before and after injection were determined with the research application immunoassay, and we calculated the time to eliminate one-half the original cTnI concentration by using a least-squares estimation method (R strip, version 4.03; Micromath Scientific, Salt Lake City, UT) in which the data were fit to a polyexponential of the form: y = aek + Through successive iterations, estimates of the values for k1 and k2 that minimized the sums of squares were determined. The alpha half-life was, by definition, the smaller of the two k values.
STATISTICAL ANALYSIS
The length of time that increases in cTnI persisted was characterized by calculating Kaplan-Meier product-limit estimates of the probability that cTnI concentrations remained increased as a function of time. This produced a "survival curve" for abnormal cTnI concentrations.
The 95% confidence intervals of this curve were calculated by using Greenwood's formula [19] . To test for statistically significant differences between the length of time that cTnI concentrations and LD 1ILD2 ratios were greater than normal, we had to take into account that both analytes were measured in the same individuals and that measurements were taken repeatedly over time in each individual. This was accomplished by tabulating for each subject (a) the number of days in which cTnI was abnormal while LD LJLD2 was normal and (b) the number of days when LD1ILD2 was abnormal while cTnI was normal. This pair of numbers for each subject was subjected to the Wilcoxon sign-rank test for a group of subjects to determine whether there was a significant difference in the number of days the two analytes were abnormal [20] .
Results
Study population. The final data set comprised 186 patients; of these, 23 patients were eliminated either because of lack of increased cTnI at any time (n = 10) or possible reinfarction (n = 13) suspected clinically, by EGG, or by biochemical criteria. Thus, 163 patients were left for analysis: 84 had an acute intervention (thrombolysis or PTCA) and 79 did not. Of those (Fig. 1B) I. From these data, the upper reference limit of the new assay would be 0.6 j.g/L as calculated from the upper reference range of the research assay studied before (3.1 pgfL [12J) .
Maximal values of cTnI. The highest cTnI values were found in those patients with Q-wave myocardial infarction who had received intervention treatment (Table 1) . Patients in the intervention group with non-Q-wave infarction had peak cTnI values similar to those in the Q-wave infarction group without intervention, but both had substantially higher values than did the patients in the non-Q-wave infarction group who did not receive intervention. #{176} Admission to critical care unit. o The day of discharge was used for this calculation for patients whose cTnl was still above-normal on the day of discharge.
normal value for cTnI on day 6 (Fig. 2) . A similar analysis could not be done with LD isoenzymes because in several patients the
LD1/LD2
ratio either was never increased, or fluctuated daily, or did not manifest a downward trend at any time.
Clearance data. Based on determinations of serial serum samples after injection of cTnI (Fig. 3) , the initial time for half of the cTnI concentrations to be eliminated (alpha distributive halflife, T112) was calculated as 4.6 ± 0.9 (SD) mm and the average 
Increased cTnI and LDI/LD2
ratios compared. For patientsin whom interventionswere performed (Fig. 4 , upper panels), whether Q-wave or non-Q-wave infarction evolved,the use of an upper reference value of 0.6 gfL for cTnI provided comparable sensitivity to LD1/LD2 0.8. These strategies were more sensitive than criteria using LD l/LD2
1. For patients who did not receive an intervention on admission (Fig. 4 , lower panels),the use of a cTnI value of >0.6 .tg/L for diagnosis initially appeared more sensitive than LD 1/LD2 0.8 early, but overall the curves were statistically comparable for the entire hospital stay. Values based on LD 1/LD2 0. 8 or an increased cTnI were both more sensitive over time for detectionof acute myocardial infarction than was LD1ILD2 1 ( Table 3 ).The median time of normalizationof cTnI ( Table 2 ) was similar when valuesof 0.4 gfL (thelower limitof detectability) were used forcTnI. Use of the lower cTnI limit led to a difference of 1 or at most 2 days to observed normalization in only a few patients.
Discussion
These data clearlydocument thatmeasurements of cTnI have sensitivity at least comparable with that of LD isoenzymes for retrospective diagnosis of acute myocardial infarction in a broad range of patients. Criteria based on cTnI were in each instance is more important, serialmeasurements of cTnI appeared somewhat more sensitive early but over time became comparably sensitive with criteria utilizing LD1ILD2 0.8. Measurement of cTnI was clearly more sensitive than the LD/LD2 = 1 cutoff value. These data indicate that criteria based on cTnI can be used without lossof sensitivity to replacemeasurements of LD isoenzymes for retrospective diagnoses of acute infarction.
The equivalentor improved sensitivity of cTnI in comparison with thatof LD isoenzymes was allwe assessedinthisstudy. However, previous studies strongly suggest that cTnI should alsobe farmore specific than LD isoenzymes.As faras has been ascertained, cTnI is found only in cardiac tissue [21] . Thus, increases in its concentrations are highly specific for cardiac injuly [12] [13] [14] . Such a finding is in keeping with the developmental biology, experimental data [21] [22] [23] , and clinical studies [12-14, 24, 25] in this area. In contrast, LD isoenzymes are distributed widely throughout the body. Substantial amounts of LD1 and LD2 can be found not only in heart but also in erythrocytes, kidney, and brain [10] . Thus hemolysis,megaloblasticanemia, renal corticaldamage, muscular dystrophies, carcinomas of the ovary and testes, and variousother pathoanatomic abnormalities reportedly can lead to increases in LD 1 and LD2 [26] . In addition,atypicalpatterns of LD isoenzymes describedin patientswith acute infarction confound diagnosis. Finally,reexpressionof LD isoenzymes in response to organ damage is known to occur [27] . Thus, although we did not directly evaluate the possibility in this study, we think it clear that cTnI will provide better specificity than LD measurements. The combination of improved specificity with comparable or even slightly bettersensitivity provides a strong rationale for substituting cTnI forLD isoenzymes in retrospective diagnoses of infarction.
Although comparable sensitivity of cTnI and LD isoenzylnes forthe diagnosisof acuteinfarction was expected, the improved early sensitivity of cTnI (in comparison with LD1ILD2) was surprising and runs counter to previously published data both for LD1 and the LDI/LD2 ratio [4] [5] [6] [7] [8] . Such findings may be attributableto the atypicalLD isoenzyme patterns,which appear to be relatedto the involvement of other organ systems affectedby the complicationsof acute infarction. For example, Rotenberg et al. described isomorphic LD patterns in 60% of patientswith cardiogenic shock [28] ; in another study, they found that 50% of patients with infarction and acute pulmonary edema showed increased LD3, and half of the patients with acute infarction and congestiveheart failure demonstrated increased LD5 [29] . They have also suggested that LD1 is a marker of right ventricular infarction [30] . Thus, concomitant diseases or the complicationsof infarction may alterthe isoenzyme pattern in these patientsand thus alterthe criteria for infarction. Reexpression of usuallyunrepresented LD forms in response to tissueinjury [27] could alsoreduce the diagnostic power of this marker, which has been reported to be excellent in patients with acutemyocardial infarction alone [6] .Regardlessof the etiology,however, the use of cTnI seems to obviatethese difficulties. The diagnostic accuracyof cTnI over time appearsdue to the continuing release of cTnI from the heart. Data for purified cTnI in dogs suggest rapid clearanceof cTnI after injection, which strongly supports such a contention.
These data also support previous suggestions that the early release of cTnI In conclusion, the presentdata stronglysupport the use of cTnI for the retrospective diagnosisof acute myocardial infarction. Such a strategyshould improve specificity as well as sensitivity for the diagnosis of myocardial infarction.
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